| Drug Name |
Diflunisal |
| Drug ID |
BADD_D00666 |
| Description |
Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis. |
| Indications and Usage |
For symptomatic treatment of mild to moderate pain accompanied by inflammation (e.g. musculoskeletal trauma, post-dental extraction, post-episiotomy), osteoarthritis, and rheumatoid arthritis. |
| Marketing Status |
approved; investigational |
| ATC Code |
N02BA11 |
| DrugBank ID |
DB00861
|
| KEGG ID |
D00130
|
| MeSH ID |
D004061
|
| PubChem ID |
3059
|
| TTD Drug ID |
D08LFZ
|
| NDC Product Code |
14593-891; 17511-129; 42973-152; 68382-530; 14539-673; 64980-181; 15308-0811; 62135-456; 0093-9222; 70771-1083 |
| UNII |
7C546U4DEN
|
| Synonyms |
Diflunisal | Dolobid | Dolocid | Dolobis | Nu-Diflunisal | Nu Diflunisal | NuDiflunisal | MK-647 | MK 647 | MK647 | Novo-Diflunisal | Novo Diflunisal | NovoDiflunisal | Apo-Diflunisal | Apo Diflunisal | ApoDiflunisal |
